Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines

William S. Holland, Danielle C. Chinn, Primo N. Lara, David R. Gandara, Philip C. Mack

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Results: The combination of MK-2206 and erlotinib resulted in synergistic growth inhibition independent of EGFR mutation status. In cell lines where HGF blocked the anti-proliferative and cytotoxic effects of erlotinib, MK-2206 could restore cell cycle arrest, but MEK inhibition was required for erlotinib-dependent apoptosis. Both AKT and MEK inhibition contributed to cell death independent of erlotinib in the T790M-containing H1975 and the EGFR-WT cell lines tested.

Purpose: Acquired resistance to erlotinib in patients with EGFR-mutant non-small cell lung cancer can result from aberrant activation of alternative receptor tyrosine kinases, such as the HGF-driven c-MET receptor. We sought to determine whether inhibition of AKT signaling could augment erlotinib activity and abrogate HGF-mediated resistance.

Methods: The effects of MK-2206, a selective AKT inhibitor, were evaluated in combination with erlotinib on a large panel of 13 lung cancer cell lines containing different EGFR or KRAS abnormalities. The activity of the combination was assessed using proliferation assays, flow cytometry and immunoblotting. The MEK inhibitor PD0325901 was used to determine the role of the MAP kinase pathway in erlotinib resistance.

Conclusions: These findings illustrate the potential advantages and challenges of combined signal transduction inhibition as a generalized strategy to circumvent acquired erlotinib resistance.

Original languageEnglish (US)
Pages (from-to)615-626
Number of pages12
JournalJournal of Cancer Research and Clinical Oncology
Issue number4
StatePublished - 2015


  • AKT
  • EGFR mutations
  • Erlotinib
  • HGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines'. Together they form a unique fingerprint.

Cite this